Regarding PFS, the pooled HR of 7.3 (95% CI 5.4–9.9, p < 0.00001) confirms the significant findings of the single-stage meta-analysis that any type of CDKN2A/B deletions are strongly associated with shortened time to meningioma progression (see Fig. 4a). Here, CDKN2A is linked to meningioma.